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Purpose: To evaluate the beneﬁ  t of titrating the concentration and exposure time of mitomycin 
C (MMC) as an adjunct to trabeculectomy.
Methods: This report consists of a retrospective study and a review of the literature. In the 
study, consecutive glaucoma patients were evaluated who underwent trabeculectomy with 
adjunctive MMC that was titrated for concentration and exposure time, based on patient’s 
risk factors for surgical failure. After minimum follow-up of 6 months, patients were divided 
into success (intraocular pressure 7–17 mmHg), hypertension (17 mmHg) and hypotony 
(7 mmHg) groups, which were compared with regard to MMC protocol and patient variables. 
The literature review included reports of trabeculectomy and adjunctive MMC with and 
without titration.
Results: One hundred and ﬁ  fty-ﬁ  ve eyes of 155 patients were studied. There were no signiﬁ  cant 
differences between the three outcome groups and MMC protocol (p  0.05). The only signiﬁ  cant 
patient variable was older age in the hypotony group (p = 0.009). The literature is conﬂ  icting 
regarding the value of titrating MMC as an adjunct in trabeculectomy.
Conclusion: The outcome of trabeculectomy with adjunctive MMC appears to represent a 
complex interaction of patient and surgical variables. While there is some support for a beneﬁ  t 
of titrating MMC according to individual patient variables, there is inadequate evidence at the 
present time to claim superiority for any MMC protocol, with or without titration.
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The introduction of mitomycin C (MMC) as an adjunct to trabeculectomy was a major 
advance in our ability to improve the intraocular pressure (IOP) lowering efﬁ  cacy of 
the procedure.1–7 With it, however, came an increased risk of serious complications, 
including hypotony maculopathy in the early postoperative course. Many investiga-
tors have attempted to ﬁ  nd protocols for the adjunctive therapy that will provide an 
acceptable balance between the beneﬁ  ts and risks.
The two MMC variables that have been evaluated most extensively are drug 
concentration and duration of application. Some surgeons have reported good 
results with a ﬁ  xed concentration/duration protocol for all patients,1–9 while others 
have attempted to improve the outcome by titrating either concentration or duration 
according to each patient’s risk for surgical failure.10–16 To date, there has been no com-
pelling evidence to support the superiority of one MMC protocol over another.
The purpose of this paper is to evaluate the beneﬁ  t of titrating MMC as an adjunct 
to trabeculectomy, based on a review of the literature and a retrospective analysis of our 
experience with titrating both concentration and duration of MMC in a series of patients 
undergoing trabeculectomy.Clinical Ophthalmology 2009:3 82
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Patients and methods
The medical records of a series of patients who underwent tra-
beculectomy with adjunctive MMC, performed at the Yale Eye 
Center by one surgeon (MBS), were retrospectively reviewed. 
The study protocol followed the guidelines of the Helsinki 
Declaration and was approved by the local ethics committee. 
For patients that underwent surgery in both eyes, one eye 
was randomly selected by coin toss for inclusion in the study. 
Concentration (0.2, 0.3, or 0.4 mg/ml) and exposure time (1–5 
minutes) of MMC for each patient were determined according 
to a protocol based on risk factors for excessive postoperative 
ﬁ  brosis (Table 1). Each risk factor was assigned a score, based 
on past experience, the sum of which was used to determine 
the protocol for MMC. In some patients, the duration of MMC 
exposure was modiﬁ  ed at the time of surgery based on the extent 
of scar tissue, bleeding, and thickness of Tenon’s capsule.
A standard trabeculectomy with a limbal-based con-
junctival ﬂ  ap was performed for all patients. A 5 × 7 mm 
block of polyvinyl acetal sponge, soaked in the predeter-
mined concentration of MMC, was placed on the sclera 
near the limbus, prior to developing the scleral ﬂ  ap, and 
the conjunctival-Tenon capsule flap was draped over 
the sponge. If the duration of MMC exposure exceeded 
two minutes, a new sponge was used for every addi-
tional two minutes. After removing the last sponge, the 
exposed tissues were copiously irrigated with balanced 
salt solution.
Preoperative data collected on each patient included age, 
ethnicity, type of glaucoma, intraocular pressure (IOP), glau-
coma medications, and previous laser or incisional surgery. 
The data collected on each follow-up visit included IOP by 
Goldmann applanation tonometry with correction for central 
corneal thickness and glaucoma medications. The minimum 
postoperative follow-up was 6 months. Outcome was based 
on the IOP of the last follow-up visit or prior to additional 
glaucoma surgery.
Success was arbitrarily deﬁ  ned as a ﬁ  nal IOP between 
7 and 17 mmHg with or without the need for glaucoma 
medication, while eyes with an IOP under 7 mmHg were 
deﬁ  ned as hypotony, and those over 17 mmHg or those 
that underwent additional glaucoma surgery were deﬁ  ned 
as hypertension. The patients were divided according to 
success, hypotony or hypertension outcome. The hypotony 
and hypertension groups were each compared to the suc-
cess group for statistical differences with regard to MMC 
concentration and exposure time, as well as age, gender, 
ethnicity, glaucoma type, preoperative IOP and prior sur-
gery, using the proportional hazard Cox regression model 
for multivariate analysis.
Results
A total of 155 eyes of 155 consecutive patients who 
underwent trabeculectomy with adjunctive MMC were 
included in the study. Patient characteristics and preopera-
tive data are shown in Table 2. The mean patient age was 
65.4 years (range, 18–89 years) and eighty-ﬁ  ve (54.8%) 
were female. Thirty-two patients (20.6%) were black and 
123 (79.4%) were nonblack. One hundred and twenty nine 
patients (83.2%) had chronic open-angle glaucoma, and the 
other forms of glaucoma included 8 (5.2%) chronic angle-clo-
sure, 9 (5.8%) pseudoexfoliation, 3 (1.9%) uveitic, 2 (1.3%) 
juvenile, and 4 (2.6%) miscellaneous types. Of the 155 eyes, 
62 (40.0%) had undergone prior argon laser trabeculoplasty 
and 44 (28.4%) had previous failed trabeculectomy. Cataract 
Table 1 Protocol for the concentration and exposure time of 
mitomycin C during trabeculectomy based on risk factors for 
excessive postoperative ﬁ  brosis
Risk factors Value
Age: less than 10 years 3
Age: 10–25 years 2
Age: 25–40 years 1
Age: greater than 70 years −1
Black 1
Sturge-Weber syndrome 2
Uveitis – inactive 2
Uveitis – active 4
Neovascular glaucoma 4
Repeat ﬁ  ltration (1 trab/no antimetabolites)§ 2
Repeat ﬁ  ltration (1 trab/5-FU)§ 3
Repeat ﬁ  ltration (1 trab/MMC)§ 4
Repeat ﬁ  ltration (2 or more trab)§ 4
PCIOL* with virgin conjunctiva in 1 or 2 
superior quadrants
1
PCIOL* with scar in superior quadrants 2
ACIOL† without vitreous in the AC‡ 2
ACIOL† with vitreous in the AC‡ 3
Aphakia 3
Other surgery with conjunctival scarring 1
Score¶ Concentration Exposure time**
1 to 2 0.2 mg/ml 1–2 minutes
3 to 4 0.3 mg/ml 3–4 minutes
5 and over 0.4 mg/ml 5–6 minutes
Notes:  *PCIOL, posterior chamber intraocular lens; †ACIOL, anterior chamber 
intraocular lens; ‡AC, anterior chamber; §trab, trabeculectomy; ¶Score = sum of risk 
factor values; **Actual exposure times were adjusted at the time of surgery according 
to bleeding, scar tissue and thickness of   Tenon capsule.Clinical Ophthalmology 2009:3 83
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extraction had been previously performed in the study eye 
of 43 (27.7%) patients. The mean preoperative IOP was 
24.0 ± 9.0 mmHg and 81 patients (52.3%) were on 3 or 
more medications in the study eye. The mean follow-up was 
15.1 months with a range of 6 to 31 months.
The mean ﬁ  nal IOP for all patients was 12.6 ± 6.1 mmHg, 
with 119 (76.8%) classiﬁ  ed as success, 21 (13.5%) as hyper-
tension and 15 (9.7%) as hypotony. The preoperative and 
surgical data for the success, hypotony, and hypertension 
groups are summarized in Table 3, and the postoperative 
data are summarized in Table 4.
Of the 119 patients who were defined as having 
a successful outcome, the mean preoperative IOP 
was 23.2 ± 9.2 mmHg and 63 patients (52.9%) were 
on 3 or more medications in the study eye. The mean ﬁ  nal 
IOP in this outcome group was 11.7 ± 2.9 mmHg, and 
8 (6.7%) required 3 or more medications postoperatively. 
Of the 21 patients in the hypertension group, the mean 
preoperative IOP was 29.1 ± 7.1 mmHg and 12 patients 
(57.1%) were on 3 or more medications. The mean ﬁ  nal IOP 
was 23.6 ± 7.1 mmHg and all were on maximum tolerable 
medical therapy. Of the 15 patients in the hypotony group, 
the mean preoperative IOP was 23.4 ± 7.7 mmHg, and 6 
patients (40.0%) were on 3 or more medications. The mean 
ﬁ  nal IOP was 4.4 ± 1.5 mmHg, with no patients receiving 
medical therapy. Outcomes were not inﬂ  uenced by the 
presence or type of cataract surgery nor by the refractive 
status of the patients.
Multivariate analysis, comparing the success and hypot-
ony groups, revealed no statistically signiﬁ  cant difference 
with regard to MMC concentration or exposure time, gender, 
ethnicity, glaucoma type, preoperative IOP, or previous sur-
gery. However, there was a statistically signiﬁ  cant difference 
with regard to age, in that the mean age of the hypotony group 
was 73.5 ± 6.1 years compared to 65.6 ± 15.2 years in the 
success group (p = 0.009).
The analysis comparing the success and hypertension 
groups revealed no statistically signiﬁ  cant difference with 
regard to MMC protocol or any patient variables.
Discussion
In 1983, Chen1 was the ﬁ  rst to report the clinical use of 
intraoperative MMC as an adjunct to glaucoma ﬁ  ltering 
surgery. Although subsequent studies have supported the 
beneﬁ  cial effects of MMC on postoperative IOP reduction 
and ﬁ  ltration bleb survival, the beneﬁ  t has been tempered by 
associated complications, including hypotony maculopathy. 
There is a considerable body of literature addressing the 
quest for a protocol that best balances the beneﬁ  ts and risks 
of intraoperative MMC as an adjunct to trabeculectomy, a 
portion of which is summarized in Table 5.
An important question in this search for the ideal pro-
tocol has been whether a single protocol is suitable for 
all patients, or whether the protocol should be titrated for 
individual patients. The two variables that have received 
the most attention in evaluating protocols are concentra-
tion and exposure time of the MMC. Early studies used 
fixed concentrations of 0.2–0.5 mg/ml for 3–5 minute 
exposures and revealed uniformly high success rates 
with regard to IOP control and low rates of hypotony.1,3–7 
Although these studies were primarily in patients who 
were at high risk of failure due to excessive fibrosis, other 
investigators have performed initial trabeculectomies in 
lower risk patients, using similar, fixed protocols to those 
described above, and also reported high success with low 
rates of hypotony.8,9
In some studies, different concentrations of MMC were 
arbitrarily assigned to patients, while the exposure time was 
kept constant in all patients.2,17–18 In each study, patients 
Table 2 Patient characteristics and preoperative data of total 
study population
Variable Total
Age (years)
mean ± SD* 65.36 ± 15.40
range 18 to 89
Gender
male 70 (45.2%)
female 85 (54.8%)
Ethnicity
black 32 (20.6%)
nonblack 123 (79.4%)
Glaucoma type
COAG† 129 (83.2%)
other 26 (16.8%)
Previous surgery
trabeculectomy 44 (28.4%)
ALT‡ 62 (40.0%)
cataract 43 (27.7%)
Preoperative IOP§ (mmHg)
mean ± SD* 24.02 ± 8.98
range 10 to 65
Preoperative medications
0–2 74 (47.7%)
3 or more 81 (52.3%)
Notes: *SD, standard deviation; †COAG, chronic open-angle glaucoma; ‡ALT, argon 
laser trabeculoplasty; §IOP, intraocular pressure.Clinical Ophthalmology 2009:3 84
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Table 3 Comparison of preoperative and surgical data for hypertension and hypotony outcome groups against success group
Variable Success* Hypertension† p value Hypotony‡ p value
No of eyes 119 21 15
Age (years) 0.132 0.009
mean ± SD§ 65.62 ± 15.24 58.05 ± 17.95 73.53 ± 6.16
range 18 to 89 19 to 82 61 to 82
Gender§ 0.376 0.239
male 56 (47.1%) 7 (33.3%) 7 (46.7%)
female 63 (52.9%) 14 (66.7%) 8 (53.3%)
Ethnicity§ 0.828 0.156
black 26 (21.8%) 5 (23.8%) 1 (6.7%)
non-black 93 (78.2%) 16 (76.2%) 14 (93.3%)
Glaucoma type§ 0.168 0.597
COAG†† 102 (85.7%) 15 (71.4%) 12 (80.0%)
other 17 (14.3%) 6 (28.6%) 3 (20.0%)
Previous surgery¶ 0.164 0.179
trabeculectomy 32 (26.9%) 6 (28.6%) 6 (40.0%)
ALT‡‡ 46 (38.7%) 8 (38.1%) 7 (46.7%)
cataract 30 (25.2%) 8 (38.1%) 5 (33.3%)
Preoperative IOP§§ (mmHg) 0.280 0.595
mean ± SD** 23.20 ± 9.19 29.10 ± 7.08 23.40 ± 7.67
range 10 to 65 19 to 48 15 to 44
Preoperative medications* 0.120 0.451
0–2 56 (47.1%) 9 (42.9%) 9 (60.0%)
3 or more 63 (52.9%) 12 (57.1%) 6 (40.0%)
MMC concentration 
(mg/ml)
0.443 0.185
mean ± SD** 0.25 ± 0.08 0.28 ± 0.09 0.29 ± 0.08
range 0.2 to 0.4 0.2 to 0.4 0.2 to 0.4
MMC duration (minutes) 0.891 0.085
mean ± SD** 2.69 ± 0.84 2.88 ± 1.04 3.03 ± 0.88
range 1 to 5 2 to 5 1 to 4
*Success, 7–17 mmHg; †Hypertension, 17 mmHg;   ‡Hypotony, 7mmHg;   §Percentage, ratio of the two variables;   ¶Percentage, % of the total in that group; **SD, standard 
deviation; ††COAG, chronic open-angle glaucoma; ‡‡ALT, argon laser trabeculoplasty; §§IOP, intraocular pressure.
receiving the higher concentration were more likely to 
develop hypotony.
Other studies have examined the impact of variable 
exposure times with MMC. An in vitro study by Jampel19 
showed that a 1-minute exposure of MMC may be as effective 
as a 5-minute exposure for inhibition of Tenon’s ﬁ  broblast 
proliferation. In clinical trials, in which a ﬁ  xed concentration 
of MMC was titrated from 0.5 to 5 minutes exposure time, 
according to individual patient’s risk factors for failure from 
excessive ﬁ  brosis, some studies also revealed no correlation 
with exposure time and either success of IOP control or risk 
of hypotony,10,11,20 while others showed a higher incidence of 
hypotony in eyes receiving the longer exposure time.21,22
In two clinical trials, the MMC concentration was kept 
constant at 0.3 or 0.4 mg/ml, and the exposure time was titrated 
between 2–3 minutes or 4–5 minutes, based on risk factors 
for surgical failure.12,13 In both series, hypotony maculopathy 
occurred more in the lower risk patients, who received the shorter 
duration of exposure. The authors interpreted these ﬁ  ndings to 
suggest that individual patient factors had a greater inﬂ  uence 
on the outcome than the exposure time of the MMC.
Other investigators have varied both concentration and 
exposure time according to risk of surgical failure, as was uti-
lized in the present study. In two of these studies, which com-
pared 0.5 mg/ml for 5 minutes with 0.4 mg/ml for 3 minutes14 
and 0.2–0.5 mg/ml for 0.5–5 minutes,15 neither study revealed Clinical Ophthalmology 2009:3 85
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a correlation between MMC variables and IOP outcome. A 
third study compared protocols of 0.2 mg/ml for 2 minutes, 
0.2 mg/ml for 4 minutes, 0.4 mg/ml for 2 minutes, or no MMC 
and found a possible dose-response relationship, with exposure 
time appearing to be more important than concentration.16
In the present study, we divided patients into three 
outcome groups: success (IOP of 7–17 mmHg with or without 
glaucoma medication); hypotony (IOP less than 7 mmHg); 
and hypertension (IOP greater than 17 mmHg or requiring 
further glaucoma surgery), and examined whether either 
MMC variable or certain patient variables correlated with 
the outcome groups. The only signiﬁ  cant variable was age, 
with the hypotony group having an older mean age than the 
success group. This ﬁ  nding is consistent with prior observa-
tions that younger patients are generally at greater risk of 
ﬁ  ltration surgery failure,23 and suggests that older patients 
require less, if any, MMC during trabeculectomy. On the other 
hand, younger patients are also at greater risk of developing 
maculopathy from hypotony,24,25 making it difﬁ  cult to select 
the optimum MMC protocol, especially in young patients.
The clinical investigations cited in this paper, including 
our study, do not provide clear support for the superiority of 
a titration protocol for MMC as an adjunct to trabeculectomy, 
compared to a ﬁ  xed protocol for all patients. While some 
studies suggest that higher concentrations and/or longer 
exposure times may increase the success of IOP control, 
but also increase the risk of hypotony,2,17,18 the majority of 
studies show no correlation between either MMC variable 
and the surgical outcome. There may be several explanations 
for the latter observation.
First, some studies only included patients who were at 
high risk of failure from excessive ﬁ  brosis, so that a single, 
ﬁ  xed protocol might have been appropriate for the major-
ity of these patients. In those studies in which the patient 
population represented a wider range of risk for surgical 
failure, and MMC variables were titrated, as in the present 
study, the lack of correlation between MMC variables and 
surgical outcome might be interpreted to suggest that other 
patient variables were responsible for the hypertension and 
hypotony outcomes. In other words, with a less appropriate 
MMC protocol, the concentration or exposure time might 
have been signiﬁ  cantly higher in the hypotony group and 
lower in the hypertension group. It is just as likely, however, 
that the lack of correlation between MMC protocol and IOP 
outcome represents an inappropriate combination of all the 
surgical and patient variables.
Our study is limited by the retrospective study design. 
In addition, it is difﬁ  cult to extrapolate our results to that of 
others, because of many variations in surgical technique. For 
example, while we applied MMC before development of the 
scleral ﬂ  ap, other surgeons apply the MMC beneath the scleral 
ﬂ  ap. These and other variations in surgical technique could 
inﬂ  uence the outcome of trabeculectomy beyond the inﬂ  uence 
of the concentration and duration of MMC application.
It seems most reasonable to conclude from the studies 
cited in this paper that the IOP outcome following trabecu-
lectomy with adjunctive MMC represents a complex inter-
action of many surgical and patient variables. In addition to 
the concentration and exposure time of MMC, the vehicle 
used to deliver the MMC and the surgical placement of the 
vehicle, as well as all the other steps in the operation, may 
well inﬂ  uence the outcome. There may also be patient vari-
ables, beyond those evaluated in the present study, such as 
the thickness of Tenon’s capsule, the degree of vascularity 
and bleeding, and possibly different receptor responses to 
MMC, that exert an inﬂ  uence on the surgical outcome.
While no claims can be made for the superiority of any 
speciﬁ  c MMC protocol in overcoming this complex problem, 
the ﬁ  ndings in the present study and a review of the literature 
are felt to support the merit of carefully evaluating the risk 
factors of each individual patient and selecting the surgical 
approach, including the use of antiﬁ  brotic agents, that is felt 
to be most appropriate for that patient.
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Table 4 Comparison of postoperative data for hypertension and 
hypotony groups against success group
Variable Success* Hypertension† Hypotony‡
Final IOP¶ (mmHg)
mean ± SD§ 11.65 ± 2.86 23.57 ± 7.10 4.40 ± 1.45
range 7 to 17 18 to 48 1 to 6
Postoperative 
medications**
0–2 111 (93.3%) 17 (81.0%) 0
3 or more 8 (6.7%) 4 (19.0%) 0
Mean follow-up 
(mos)
15.21 ± 7.10 14.33 ± 6.28 15.07 ± 6.60
range 6 to 31 6 to 27 6 to 30
Notes: *Success, 7–17 mmHg; †Hypertension, 17 mmHg; ‡Hypotony, 7 mmHg; §SD, 
standard deviation; ¶IOP, intraocular pressure; **Percentage, ratio of the two variables.Clinical Ophthalmology 2009:3 86
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Table 5 Summary of literature evaluating mitomycin C (MMC) as an adjunct to trabeculectomy
Authors Number of eyes Duration of follow-up 
(months)
MMC concentration 
(mg/ml)
MMC duration 
(minutes)
Results
Success Hypotony 
(eyes)
Kitazawa et al 1991 17 7 to 12 0.2 5 88% 0
Skuta et al 1992 20 6 0.5 5 95% 1
Katz et al 1995 20 26 to 38 0.5 5 81.3% 1
Palmer 1991 33 6 to 42 0.2 5 84% 1
El Sayyad et al 2000 68 12 0.3 3 71%–82% 4
Nuijts et al 1997 25 12 0.2 5 92% 1
Scott et al 1998 89 24 0.5 5 85% 4
Kitazawa et al 1993 22 6 to 17 a) 0.2 a) 5 100% 2
b) 0.02 b) 5 63.6% 0
Sanders et al 1999 50 12 a) 0.2 a) 2 72.0% 2
b) 0.4 b) 2 70.8% 3
Chen et al 1990 59 12 to 76 0.1–0.4 5 77.8% 2
Cohen et al 1997 106 14 a) 0.5 a) 0.5–1 * 1
b) 0.5 b) 1–3 4
Perkins et al 1998 68 36 0.5 0.5–5 * 3
Shields et al 1993 59 2 to 14 a) 0.4 a) 2–3 91.2% 4
b) 0.4 b) 4–5 72.2% 0
Stone et al 1998 57 11.9 a) 0.3 a) 1–3 * 3
b) 0.3 b) 4–5 0
Megevand et al 
1995
73 18 a) 0.2 a) 2 88% 2
b) 0.2 b) 5 84% 1
Kim et al 1998 88 3 to 12 a) 0.5 a) 0.5–1 † 29
b) 0.5 b) 3–5 20
Zacharia et al 1993 52 2 to 12 0.4 3.5–7 † 17
Neelakantan et al 
1994
93 a) 0.4 a) 3 *
b) 0.5 b) 5
Cheung et al 1997 157 36 0.2–0.5 0.5–5 *
Robin et al 1997 300 12 a) 0.2 a) 2 79.4% 2
b) 0.2 b) 4 83.3% 2
c) 0.4 c) 2 85.7% 2
Notes: *No correlation between MMC variable and outcome; †Statistically signiﬁ  cant association between MMC variable and outcome.
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